Skip to main content
. Author manuscript; available in PMC: 2024 Oct 1.
Published in final edited form as: Eur Urol Oncol. 2023 Apr 20;6(5):516–524. doi: 10.1016/j.euo.2023.03.008

Fig. 3 –

Fig. 3 –

On-treatment mR-scores correlated with response. (A) Weak correlation between on-treatment and pretreatment mR-scores. Spearman correlation coefficient R = 0.39 (p = 0.003). (B) On-treatment mR-scores in patients receiving different NAC regimens.

DDMVAC + CYST = dose-dense methotrexate, vinblastine, adriamycin, and cisplatin followed by cystectomy; GC + CYST = gemcitabine-cisplatin followed by cystectomy; mR-score = methylation-based response score; NAC = neoadjuvant chemotherapy; NR = nonresponder; R = responder.